New York State Common Retirement Fund’s Allogene Therapeutics ALLO Stock Holding History

New York State Common Retirement Fund’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$100K	Buy	48,097 +20,200	+72%	+$44.4K	﹤0.01%	2689
2026 Q1	$68.1K	Hold	27,897	–	–	﹤0.01%	2705
2025 Q4	$38.2K	Hold	27,897	–	–	﹤0.01%	2974
2025 Q3	$34.6K	Hold	27,897	–	–	﹤0.01%	3028
2025 Q2	$31.5K	Hold	27,897	–	–	﹤0.01%	3052
2025 Q1	$40.7K	Hold	27,897	–	–	﹤0.01%	2840
2024 Q4	$59.4K	Hold	27,897	–	–	﹤0.01%	2806
2024 Q3	$78.1K	Hold	27,897	–	–	﹤0.01%	2708
2024 Q2	$65K	Buy	27,897 +61	+0.2%	+$180	﹤0.01%	3024
2024 Q1	$124K	Buy	27,836 +77	+0.3%	+$321	﹤0.01%	2649
2023 Q4	$89.1K	Sell	27,759 -187	-0.7%	-$530	﹤0.01%	2799
2023 Q3	$88.6K	Buy	27,946 +266	+1%	+$1.17K	﹤0.01%	2787
2023 Q2	$138K	Sell	27,680 -101	-0.4%	-$546	﹤0.01%	2660
2023 Q1	$137K	Sell	27,781 -29,416	-51%	-$189K	﹤0.01%	2728
2022 Q4	$360K	Sell	57,197 -49	-0.1%	-$454	﹤0.01%	2475
2022 Q3	$618K	Buy	57,246 +8,380	+17%	+$114K	﹤0.01%	2223
2022 Q2	$557K	Sell	48,866 -122	-0.2%	-$1.08K	﹤0.01%	2308
2022 Q1	$446K	Buy	48,988 +22	+0%	+$229	﹤0.01%	2457
2021 Q4	$731K	Sell	48,966 -171	-0.3%	-$3.02K	﹤0.01%	2234
2021 Q3	$1.26M	Sell	49,137 -9,612	-16%	-$228K	﹤0.01%	2008
2021 Q2	$1.53M	Buy	58,749 +9,849	+20%	+$281K	﹤0.01%	2025
2021 Q1	$1.73M	Hold	48,900	–	–	﹤0.01%	1862
2020 Q4	$1.23M	Buy	48,900 +4,400	+10%	+$143K	﹤0.01%	1945
2020 Q3	$1.68M	Hold	44,500	–	–	﹤0.01%	1663
2020 Q2	$1.91M	Buy	44,500 +9,700	+28%	+$351K	﹤0.01%	1557
2020 Q1	$677K	Hold	34,800	–	–	﹤0.01%	1912
2019 Q4	$904K	Sell	34,800 -5,000	-13%	-$138K	﹤0.01%	1998
2019 Q3	$1.08M	Hold	39,800	–	–	﹤0.01%	1952
2019 Q2	$1.07M	Buy	39,800 +18,500	+87%	+$515K	﹤0.01%	1983
2019 Q1	$616K	Buy	+21,300	New	+$618K	﹤0.01%	2204

Other funds holding ALLO

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

RBI

Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

HDA

Harold Davidson & Associates Los Angeles, California $231M AUM 35.6% 1-Year Est. Return

New York State Common Retirement Fund's ALLO Position: Q2 2026 in Review

New York State Common Retirement Fund increased its Allogene Therapeutics (ALLO) stake by 72% in Q2 2026, buying an estimated $44.4K and bringing the position to 48,097 shares worth $100K. The position accounts for ﹤0.01% of the portfolio, ranked #2689.

New York State Common Retirement Fund first reported a position in ALLO in Q1 2019 and has held it in 30 quarters since. The position peaked at $1.91M in Q2 2020. 46 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

New York State Common Retirement Fund held 48,097 shares of Allogene Therapeutics worth $100K as of Q2 2026.
New York State Common Retirement Fund bought 20,200 Allogene Therapeutics shares in Q2 2026, an estimated $44.4K.
Allogene Therapeutics made up ﹤0.01% of New York State Common Retirement Fund's portfolio in Q2 2026, its #2689 holding.
New York State Common Retirement Fund first reported a position in Allogene Therapeutics in Q1 2019 and has held it in 30 quarters since.
New York State Common Retirement Fund's Allogene Therapeutics position peaked at $1.91M in Q2 2020.
46 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.